Revance Therapeutics Inc

NASDAQ:RVNC   3:59:54 PM EDT
14.01
-0.16 (-1.16%)
Products

Revance Says BLA For Daxibotulinumtoxina For Injection Remains Under FDA Review

Published: 10/13/2021 01:05 GMT
Revance Therapeutics Inc (RVNC) - Revance Continues to Anticipate FDA Approval of Daxibotulinumtoxina for Injection for the Treatment of Glabellar Lines in 2021.
Revance Therapeutics Inc - Bla for Daxibotulinumtoxina for Injection Remains Under FDA Review.